CMDT Master’s
Blueprint:
2026/2027
Advanced
Practice
Clinical
Judgment
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Questions 1–15): Testing
2026/2027 definitions and core standard shifts.
○ Section 2: Professional Simulation (Questions 16–40): High-stakes,
variable-dependent immediate actions.
, ○ Section 3: Grandmaster Synthesis (Questions 41–66): Multi-system,
crisis-averting diagnostic reasoning.
PART I: THE PRIMER
Mastering the 2026/2027 clinical architecture separates the definitive diagnostician from the
algorithmic novice. High-level professional success demands the immediate, flawless synthesis
of metabolic, renal, and cardiopulmonary guidelines to avert catastrophic patient outcomes.
● The AHA PREVENT Rule: Pharmacotherapy is mandated for Stage 1 Hypertension
(130-139/80-89 mm Hg) if 10-year Cardiovascular-Kidney-Metabolic risk is ≥ 7.5%.
● The KDIGO Iron Hard Deck: Absolute contraindication for intravenous iron in Chronic
Kidney Disease (CKD) anemia occurs when Ferritin > 700 ng/mL or Transferrin Saturation
(TSAT) ≥ 40%.
● Surviving Sepsis: Immediate 30 mL/kg fluid resuscitation is required for lactate ≥ 4.0
mmol/L or profound hypotension, with blood cultures secured beforehand.
● AHA/ASA Stroke: Post-thrombolytic blood pressure must remain < 180/105 mm Hg;
however, intensive lowering < 140 mm Hg post-Endovascular Thrombectomy (EVT)
causes ischemic harm and is forbidden.
● The ACG H. Pylori Ban: Empiric proton-pump inhibitor (PPI) and clarithromycin triple
therapy is obsolete; initiate optimized Bismuth Quadruple Therapy (BQT).
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application (Questions 1–15)
Q1: According to the 2026 American Heart Association (AHA) guidelines, a 45-year-old client
presents with a confirmed systolic blood pressure of 134 mm Hg and diastolic of 84 mm Hg. The
client has no known history of cardiovascular disease, diabetes, or CKD. Which calculation tool
is the MOST APPROPRIATE INITIAL metric to guide pharmacologic intervention? A) The
Pooled Cohort Equations (PCE) to assess isolated atherosclerotic risk. B) The PREVENT-CVD
calculator to assess 10-year total cardiovascular and heart failure risk. C) The Framingham Risk
Score adjusted for patient ethnicity. D) The Kidney Disease: Improving Global Outcomes
(KDIGO) cardiovascular stress index calculator.
● The Answer: B (The PREVENT-CVD calculator to assess 10-year total cardiovascular
and heart failure risk.)
● Distractor Analysis:
○ A is incorrect: The PCE was retired due to its failure to account for heart failure and
reliance on binary race variables.
○ C is incorrect: The 2026 PREVENT model explicitly removes race as a biological
variable, substituting the Social Deprivation Index (SDI).
○ D is incorrect: KDIGO dictates renal guidelines, not primary atherosclerotic or heart
failure risk estimation.
The Mentor's Analysis: The transition from PCE to the PREVENT calculator is a defining
cardiovascular paradigm shift. By combining atherosclerotic cardiovascular disease (ASCVD)
with heart failure (HF) metrics and removing race in favor of zip-code-based social deprivation
indices, the practitioner targets the true pathophysiologic and socioeconomic drivers of disease.
, Calculator Feature Legacy PCE 2026 PREVENT
Outcomes Predicted ASCVD only ASCVD + Heart Failure
Demographic Inputs Race (Binary) Social Deprivation Index (Zip)
Metabolic Inputs Standard Lipids Adds UACR, HbA1c, eGFR
Q2: Under the 2026 American Diabetes Association (ADA) Standards of Care, a patient with
prediabetes and a Body Mass Index (BMI) of 31 kg/m² seeks to prevent progression to Type 2
Diabetes. Which weight loss target is the MINIMUM REQUIRED intervention goal to effectively
alter the cardiometabolic disease trajectory? A) 2-3% of total body weight. B) 5-7% of total body
weight. C) 10% or more of total body weight. D) 15-20% of total body weight.
● The Answer: B (5-7% of total body weight.)
● Distractor Analysis:
○ A is incorrect: This reduction is insufficient to reliably alter systemic insulin
resistance.
○ C is incorrect: While >10% is the target for Type 2 Diabetes remission, the baseline
minimum target for preventing progression in prediabetes is 5-7%.
○ D is incorrect: This is an optimal surgical or advanced pharmacotherapy target, but
exceeds the minimum required definition.
The Mentor's Analysis: Precision in target-setting dictates treatment aggressiveness. The
practitioner must differentiate the 5-7% prevention threshold from the >10% remission threshold.
Establishing the exact percentage prevents premature escalation to bariatric surgery or
inappropriate dosing of GLP-1 receptor agonists.
Q3: The 2024/2026 American College of Gastroenterology (ACG) guidelines regarding
Helicobacter pylori eradication strongly dictate a shift in first-line empiric therapy for
treatment-naïve patients. Which regimen is STRONGLY RECOMMENDED over legacy
treatments? A) Empiric PPI-clarithromycin-amoxicillin triple therapy for 10 days. B) Bismuth
Quadruple Therapy (BQT) for 14 days. C) Concomitant therapy consisting of a PPI, amoxicillin,
metronidazole, and clarithromycin. D) High-dose PPI dual therapy with levofloxacin.
● The Answer: B (Bismuth Quadruple Therapy (BQT) for 14 days.)
● Distractor Analysis:
○ A is incorrect: Clarithromycin resistance has spiked; utilizing it without susceptibility
testing constitutes substandard care.
○ C is incorrect: Concomitant therapy is explicitly NOT recommended in
treatment-naïve patients due to rising levofloxacin and clarithromycin resistance.
○ D is incorrect: Levofloxacin resistance prevents its use as a first-line empiric agent.
The Mentor's Analysis: Antibiotic stewardship requires abandoning failed legacy regimens.
BQT is the definitive empiric standard. If a Potassium-Competitive Acid Blocker (PCAB) like
vonoprazan is available, it serves as an acceptable alternative, but clarithromycin is effectively
obsolete as an empiric choice.
Q4: A patient with CKD Stage G4 presents with anemia. The practitioner evaluates iron indices
to determine the safety of an intravenous iron infusion. According to the 2026 KDIGO Anemia in
CKD Guideline, at which threshold MUST the practitioner WITHHOLD iron therapy? A) Ferritin >
500 ng/mL or TSAT ≥ 30% B) Ferritin > 700 ng/mL or TSAT ≥ 40% C) Ferritin > 800 ng/mL or
TSAT ≥ 50% D) Ferritin > 1000 ng/mL or TSAT ≥ 55%
● The Answer: B (Ferritin > 700 ng/mL or TSAT ≥ 40%)
● Distractor Analysis:
○ A is incorrect: These are older, conservative thresholds that restrict necessary iron
delivery in hemodialysis patients.
Blueprint:
2026/2027
Advanced
Practice
Clinical
Judgment
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
● PART II: THE ELITE TEST BANK
○ Section 1: Foundational Syntax & Application (Questions 1–15): Testing
2026/2027 definitions and core standard shifts.
○ Section 2: Professional Simulation (Questions 16–40): High-stakes,
variable-dependent immediate actions.
, ○ Section 3: Grandmaster Synthesis (Questions 41–66): Multi-system,
crisis-averting diagnostic reasoning.
PART I: THE PRIMER
Mastering the 2026/2027 clinical architecture separates the definitive diagnostician from the
algorithmic novice. High-level professional success demands the immediate, flawless synthesis
of metabolic, renal, and cardiopulmonary guidelines to avert catastrophic patient outcomes.
● The AHA PREVENT Rule: Pharmacotherapy is mandated for Stage 1 Hypertension
(130-139/80-89 mm Hg) if 10-year Cardiovascular-Kidney-Metabolic risk is ≥ 7.5%.
● The KDIGO Iron Hard Deck: Absolute contraindication for intravenous iron in Chronic
Kidney Disease (CKD) anemia occurs when Ferritin > 700 ng/mL or Transferrin Saturation
(TSAT) ≥ 40%.
● Surviving Sepsis: Immediate 30 mL/kg fluid resuscitation is required for lactate ≥ 4.0
mmol/L or profound hypotension, with blood cultures secured beforehand.
● AHA/ASA Stroke: Post-thrombolytic blood pressure must remain < 180/105 mm Hg;
however, intensive lowering < 140 mm Hg post-Endovascular Thrombectomy (EVT)
causes ischemic harm and is forbidden.
● The ACG H. Pylori Ban: Empiric proton-pump inhibitor (PPI) and clarithromycin triple
therapy is obsolete; initiate optimized Bismuth Quadruple Therapy (BQT).
PART II: THE ELITE TEST BANK
Section 1: Foundational Syntax & Application (Questions 1–15)
Q1: According to the 2026 American Heart Association (AHA) guidelines, a 45-year-old client
presents with a confirmed systolic blood pressure of 134 mm Hg and diastolic of 84 mm Hg. The
client has no known history of cardiovascular disease, diabetes, or CKD. Which calculation tool
is the MOST APPROPRIATE INITIAL metric to guide pharmacologic intervention? A) The
Pooled Cohort Equations (PCE) to assess isolated atherosclerotic risk. B) The PREVENT-CVD
calculator to assess 10-year total cardiovascular and heart failure risk. C) The Framingham Risk
Score adjusted for patient ethnicity. D) The Kidney Disease: Improving Global Outcomes
(KDIGO) cardiovascular stress index calculator.
● The Answer: B (The PREVENT-CVD calculator to assess 10-year total cardiovascular
and heart failure risk.)
● Distractor Analysis:
○ A is incorrect: The PCE was retired due to its failure to account for heart failure and
reliance on binary race variables.
○ C is incorrect: The 2026 PREVENT model explicitly removes race as a biological
variable, substituting the Social Deprivation Index (SDI).
○ D is incorrect: KDIGO dictates renal guidelines, not primary atherosclerotic or heart
failure risk estimation.
The Mentor's Analysis: The transition from PCE to the PREVENT calculator is a defining
cardiovascular paradigm shift. By combining atherosclerotic cardiovascular disease (ASCVD)
with heart failure (HF) metrics and removing race in favor of zip-code-based social deprivation
indices, the practitioner targets the true pathophysiologic and socioeconomic drivers of disease.
, Calculator Feature Legacy PCE 2026 PREVENT
Outcomes Predicted ASCVD only ASCVD + Heart Failure
Demographic Inputs Race (Binary) Social Deprivation Index (Zip)
Metabolic Inputs Standard Lipids Adds UACR, HbA1c, eGFR
Q2: Under the 2026 American Diabetes Association (ADA) Standards of Care, a patient with
prediabetes and a Body Mass Index (BMI) of 31 kg/m² seeks to prevent progression to Type 2
Diabetes. Which weight loss target is the MINIMUM REQUIRED intervention goal to effectively
alter the cardiometabolic disease trajectory? A) 2-3% of total body weight. B) 5-7% of total body
weight. C) 10% or more of total body weight. D) 15-20% of total body weight.
● The Answer: B (5-7% of total body weight.)
● Distractor Analysis:
○ A is incorrect: This reduction is insufficient to reliably alter systemic insulin
resistance.
○ C is incorrect: While >10% is the target for Type 2 Diabetes remission, the baseline
minimum target for preventing progression in prediabetes is 5-7%.
○ D is incorrect: This is an optimal surgical or advanced pharmacotherapy target, but
exceeds the minimum required definition.
The Mentor's Analysis: Precision in target-setting dictates treatment aggressiveness. The
practitioner must differentiate the 5-7% prevention threshold from the >10% remission threshold.
Establishing the exact percentage prevents premature escalation to bariatric surgery or
inappropriate dosing of GLP-1 receptor agonists.
Q3: The 2024/2026 American College of Gastroenterology (ACG) guidelines regarding
Helicobacter pylori eradication strongly dictate a shift in first-line empiric therapy for
treatment-naïve patients. Which regimen is STRONGLY RECOMMENDED over legacy
treatments? A) Empiric PPI-clarithromycin-amoxicillin triple therapy for 10 days. B) Bismuth
Quadruple Therapy (BQT) for 14 days. C) Concomitant therapy consisting of a PPI, amoxicillin,
metronidazole, and clarithromycin. D) High-dose PPI dual therapy with levofloxacin.
● The Answer: B (Bismuth Quadruple Therapy (BQT) for 14 days.)
● Distractor Analysis:
○ A is incorrect: Clarithromycin resistance has spiked; utilizing it without susceptibility
testing constitutes substandard care.
○ C is incorrect: Concomitant therapy is explicitly NOT recommended in
treatment-naïve patients due to rising levofloxacin and clarithromycin resistance.
○ D is incorrect: Levofloxacin resistance prevents its use as a first-line empiric agent.
The Mentor's Analysis: Antibiotic stewardship requires abandoning failed legacy regimens.
BQT is the definitive empiric standard. If a Potassium-Competitive Acid Blocker (PCAB) like
vonoprazan is available, it serves as an acceptable alternative, but clarithromycin is effectively
obsolete as an empiric choice.
Q4: A patient with CKD Stage G4 presents with anemia. The practitioner evaluates iron indices
to determine the safety of an intravenous iron infusion. According to the 2026 KDIGO Anemia in
CKD Guideline, at which threshold MUST the practitioner WITHHOLD iron therapy? A) Ferritin >
500 ng/mL or TSAT ≥ 30% B) Ferritin > 700 ng/mL or TSAT ≥ 40% C) Ferritin > 800 ng/mL or
TSAT ≥ 50% D) Ferritin > 1000 ng/mL or TSAT ≥ 55%
● The Answer: B (Ferritin > 700 ng/mL or TSAT ≥ 40%)
● Distractor Analysis:
○ A is incorrect: These are older, conservative thresholds that restrict necessary iron
delivery in hemodialysis patients.
